Abstract
This paper is my annual oration on prevention of multiple organ dysfunction syndrome (MODS) and multiple organ failure (MOF) at the Organ Failure Academy in Trieste, Italy. All we can do to treat MODS and MOF is organ support. Therefore, prevention is the key — supporting organ and system function before dysfunction or failure occur. There are many ways we can do that in 2002.1 have reviewed them [1,2]. The future was predicted recently by a number of authorities in intensive care medicine and anaesthesiology who were plenary speakers at the recent Society of Critical Care Medicine meeting. Buchman talked about the new junction of genomics and critical care as it exists today and as it is likely to evolve tomorrow, van der Pol reviewed tissue factor and activated protein C, which may also improve other inflammatory pathways. Abraham reviewed genetic analyses and predicted that they may help determine future therapies in critically ill patients. Tracy said that it should be feasible to study both vagus nerve stimulation and anti-HMGB-1 (a latent mediator). Vincent reviewed future therapeutic interventions that will likely involve multiple/combination therapies. Genomics and critical care, tissue factor and activated protein C, genetic analysis, latent mediators, and other problems, and the possibility of multiple or combination therapy are on the horizon. This last recommendation comes because factors to either block or stimulate individual mediators or anti-inflammatory agents have failed. The real question is how quickly these predictions will help our patients. The world of science and molecular biology is exciting but much of it is pure science and is not yet related to improved care in the intensive care unit (ICU) or operating room.
Chapter PDF
Similar content being viewed by others
Keywords
- Septic Shock
- Severe Sepsis
- Acute Respiratory Distress Syndrome
- Septic Patient
- Chronic Granulomatous Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Baue AE (2000) MODS/MOF A complication of progress in organ support. Shock 13:A7
Baue AE (2002) Sepsis and organ dysfunction — basics, controversies, rationale. In: Baue AE, Berlot TG, Gullo A, Vincent JL (eds) Springer-Verlag Italia, Milan, pp 19–34
Rees J (2002) Complex disease and the new clinical sciences. Science 296:698–672
Simon H (1991) Models of my life. Basic Books, NY
Nathan DC (2002) Careers and translational clinical research - historical perspectives, future challenges. JAMA 287:2424–2427
Brenneman FD, Wright JG, Kennedy ED, et al (1999) Outcomes research in surgery. World J Surg 23:1220–1223
Sackett DL, Rosenberg WMC (1995) The need for evidence-based medicine. J Roy Soc Med 88:620–624
Cohen J (1999) The failure of clinical trials in sepsis. Curr Opm Healthcare X:339–340
Marshall JC, Vincent JL, Fink MP, et al Measures, markers and mediators: towards a staging system for clinical sepsis. Crit Care Med (in press)
Torpy JM (2002) New threats and old enemies — challenges for critical care medicine. JAMA 287:1513–1515
Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350
Kamradt T, Mitchison NA (2001) Tolerance and autoimmunity. N Engl J Med 344:655–664
Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916
Sartor RB (2000) New therapeutic approaches to Crohn’s disease. N Engl J Med 342:1664–1666
Safar PJ, Kochanek PM (2002) Genes, microbes, and T cells — new therapeutic targets in Crohn’s disease. N Engl J Med 346:614–616
Gallin JI, Malech RS, Weening RS, et al (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–516
Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349–1356
Dayer JM, Krane SM (2002) Anti-TNF-alpha therapy for ankylosing spondylitis — a specific or nonspecific treatment? N Engl J Med 346:1399–1400
Saenz JJ, Izura JJ, Manrique A, et al (2001) Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med 27:970–977
Haupt W, Beyer A, Schoolmann S, et al (2000) Early depression and late improvement of HLA-DR and LPS-stimulated IL-6/TNfa production in survivors of sepsis. Shock 13:A498
Schroeder S, Wichers M, Klingmueller D (2001) The hypothalamic-pimitary adrenal axis of patients with severe sepsis: altered response to corticotropin releasing hormone. Crit Care Med 29:310–316
Fischer G, Schneider EM, Moldawer LL, et al (2001) CD64 surface expression on neutrophils is transiently upregulated in patients with septic shock. Intensive Care Med 27:1848–1852
Hirsh M, Mahamid E, Bashenko Y, et al (2001) Overexpression of the high-affinity Fc X receptor (CD64) is associated with leukocyte dysfunction in sepsis. Shock 16:102–108
Cobb JP, Laramie JM, Qiu Y, et al (2001) Broad-scale splenic gene expression profihng in septic patients with multiple organ dysfunction syndrome (abstract). Soc U Surgeons Program 37
Krafte-Jacobs B, Bock GH (2001) Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock. Crit Care Med 29:S151-S155
Pellegrini J, Puyana JC, Lapchak P, Miller C (2001) A membrane TNEa/TNER ratio correlates to MOD score and mortahty (abstract). Shock 18:20
Mitsuoka H, Kistler EB, Schmid-Schonbein GW (2002) Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock. Shock 17:205–209
Kasai T, Endo S, Yamada Y, et al (1999) Nitrite/nitrate and type II phospholipase A2 increase in patients with multiple organ dysfunction syndrome. Shock [Suppl 12]:A62
Weighardt H, Heidecke CD, Westerhold A, et al (2002) Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 235:560–565
Oberholzer A, Steckholzer U, Kurimoto M, et al (2001) Interleukin-18 plasma levels are increased in patients with sepsis compared to severe injured patients. Shock 16:411–414
Hauser AR, CObb E, Bodi M, et al (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-assisted pneumonia caused by Pseudomonas aeurginosa. Crit Care Med 30:521–524
Abraham E (2002) Mechanisms of cytokine activation in septic patients in the medical ICU. SCCM Symposium Highlights, pp 19–22
Mavrommatis AC, Theodoridis T, Economou M, et al (2001) Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 27:1853–1859
Barth E, Fischer G, Maier A, et al (2000) Peaks of endogenous G-CSF semm concentrations are followed by an increase in burst activity of neutrophils in most patients with severe sepsis and septic shock. Shock 13:A414
Luger A, Graf H, Schwarz HP, et al (1986) Decreased semm interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med 14:458–463
Nijsten MWN, Duis HJT, Zijlstra JG, et al (2000) Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 28:3843–3846
Papathanassoglou EDE, Moynihan JA, McDermott MP, et al (2001) Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med 29:709–718
Bmemmer-Smith S, Stuber F, Schroeder S (2001) Protective functions of intracellular heat-shock protein (HSP) 70-expression in patients with severe sepsis. Intensive Care Med 27:1835–1841
Liacos C, Katsaragakis S, Konstadoulakis MM, et al (2001) Apoptosis in cells of bronchoalveolar lavage: a cellular reaction in patients who die with sepsis and respiratory failure. Crit Care Med 29:2310
Calvano JE, Agnese DM, Hahm SJ, et al (2001) Human toll-like receptor-4 (hTLR4) mutations are associated with an increased risk of gram-negative infections and increased mortahty. Surg Fomm 52:133–134
Bakker J, Gris P, Coffemils M, et al (1996) Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg 171:221–226
Hartemink KJ, Groeneveld J, Groot MCM de, et al (2001) a-Atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 29:80–85
Claeys R, Vinken S, Spapen H, et al (2002) Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 30:757–762
Russwurm S, Vickers J, Meier-Hellmann A, et al (2002) Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 17:263–268
Tavares-Murta BM, Zaparoh M, Ferreira RB, et al (2002) Failure of neutrophil chemotactic function in septic patients. Crit Care Med 30:1056–1061
Stephan F, Yang K, Tankovic J, et al (2002) Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30:315–322
Bemard G, Vincent J, Laterre PF, et al (2001) The PROWESS Trial — efficacy and safety of recombinant human-activated protein C for severe sepsis. N Engl J Med 344:699–708
Grinnell BW, Joyce D (2001) Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29:S53-S61
Bemard G, Artigas A, Dellinger P, et al (2001) Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis. Crit Care Med 29:S75-S77
Raufhake C, Schleuter B, Driller B, et al (1999) Tumor necrosis factor gene polymorphism in critically ill surgical patients: its influence on susceptibihty to and outcome of sepsis (abstract). Crit Care Med 27:A97
Gibot S, Cariou A, Drouet L, et al (2002) Association between a genomic polymorphism within the CD 14 locus and septic shock susceptibility and mortahty rate. Crit Care Med 30:969–973
Ma P, Chen D, Pan J, Du B (2002) Genomic polymorphism with interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 30:1046–1050
Kumar A, Kumar A, Parrillo JE (2002) Interleukin-1 gene cluster polymorphisms: all in the family. Crit Care Med 30:1168–1169
Randolph AG (2002) Mining for the genetic determmants of septic shock: when is it really gold? Crit Care Med 30:1161–1163
Cariou A, Chiche JD, Charpentier J, et al (2002) The era of genomics: impact on sepsis clinical trial design. Crit Care Med 30:S341-S348
Willett WC (2002) Balancing life-style and genomics research for disease prevention. Science 296:695–698
Strohman R (2002) Maneuvering in the complex path from genotype to phenotype. Science 296:701–703
Roos D, Winterboum CC (2002) Lethal weapons. Science 296:669–670
Baue AE, Gunther B, Hartl W, et al (1984) Altered hormonal activity in severely ill patients after injury or sepsis. Arch Surg 119:1125–1132
Sibbald WS, Short A, et al (1977) Variations in adreno-corticol responsiveness during severe bacterial infection: umecognized adreno-corticol insufficiency in severe bacterial infections. Ann Surg 186:29–33
Leeuwen HJ van, Brüggen T van der, Asbeck BS van, Boereboom FTJ (2001) Effect of corticosteroids on nuclear factor-kB activation and hemodynamics in late septic shock. Crit Care Med 29:1074–1077
Annane D (2000) Effects of the combination of hydrocortisone (HC) — fludro-cortisone (FC) on mortahty in septic shock. Crit Care Med 28: [Suppl] A63
Beishuizen A, Thijs LG, Vermes I (2001) Patterns of corticosteroid-binding globulin and the free Cortisol index during septic shock and multitrauma. Intensive Care Med 27:1584–1591
Kees H, Polderman JJS, Wester JP (2000) High incidence of adreno-cortical insufficiency in patients with a mutiple organ dysfunction syndrome. Crit Care Med 28:a49
Zaloga GP (2001) Sepsis-induced adrenal deficiency syndrome. Crit Care Med 29:88–89
Namba H, Fujimura N, Imaizumi H, et al (2000) Effect of methylprednisolone on inflammatory response in septic shock patients. Crit Care Med 28: [Suppl] A613/T201
Burton TM (2002) Cheap drugs that halt fatal sepsis unused. The Day. New London, Conn., Saturday May 18
Ligtenberg JJM, Girbes ARJ, Beentjes JAM, et al (2001) Hormones in the critically ill patient: to intervene or not to intervene? Intensive Care Med 27:1567–1577
Sharshar T, Calier R, Blanchard A, et al (2002) Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 30:497–500
Meduri GU, Cinn AJ, Leeper KV (1994) Corticosteroid rescue treatment of progressive fibro- proliferation in late ARDS. Chest 105:1516–1527
Nagelschmidt M, Neugebauer E (2000) Improvement of outcome after abdominal surgery by perioperative high dose methylprednisolone. Shock 13:A635
Brown CJ, Buie WD (2001) Perioperative stress dose steroids: do they make a difference? J Am Coll Surg 193:678–686
Koo DJ, Jackman D, Chaudry IH, Wang P (2001) Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 29:618–622
Woolf PD (2001) Adrenal tea leaves: is the adrenal response to sepsis discernible? Crit Care Med 29:450–451
Matot I, Sprung CL (1998) Corticosteroids in septic shock: resurrection or the last rites? Crit Care Med 26:627–630
Briegel J (2000) Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics? Intensive Care Med 26:1723–1726
Polderman KH, Spijkstra JJ, Wester JP, et al (2000) High incidence of adrenocortical insufficiency in patients with the multiple organ dysfunction syndrome. Crit Care Med 28:A49
Schultz SG (1996) Homeostasis, humpty dumpty and integrative biology news. Physiol Sci 11:238–246
Buchman TG (1996) Physiologic stability and physiologic state. J Trauma 41:599–605
Siegel JH, Farrell EF, Goldwyn RM, Friedman HP (1972) The surgical imphcations of physio logic patterns in myocardial infarction shock. Surgery 72:126–141
Chambers NK, Buchman TG (2001) Shock at the millennium H. Cannon WB and Henderson L. Shock 16:278–284
Goodwin JS (1997) Chaos and the hmits of modem medicine. JAMA 278:1399–1400
Latour B (1998) From the world of science to the world of research. Science 280:208–209
Goldberger AL, Rigney DR, West BJ (1990) Chaos and fractals in human physiology. Sci Am 262:43–49
Seely AJE, Christou NV (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex non-linear systems. Crit Care Med 28:2193–2200
Knox J, Demling R, Wilmore D, et al (1995) Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma 39:526–530
Kirton O, Windsor J, Civetta J, et al (1996) Persistent uncorrected intermucosal pH in injured patient: the impact of splechnic and anti-oxidant therapy. Crit Care Med 24:80–82
Baue AE (2001) Bad and good news in prevention and management of sepsis and MODS. Minerva Anestesiol 67:773–783
Baue AE (2001) Semmelweis Lecture: sepsis research — What did we do wrong? What would Semmelweis do today? Shock 16:1–8
Candiani NA (2001) Infection surveillance in ICUs. Minerva Anestesiol 67:839–847
Barie PS (2001) Infection control is a matter of self control. Surg Infect 2:253–254
Murray JA, Belzberg H, Chen D, et al (1999) Prospective evaluation of early fluconazole use in the surgical ICU. Shock 18:35–40
Zandstra DF, Saene HKF van (2001) Selective decontamination of the digestive system as infection prevention in the critically ill. Does it lead to resistance? Minerva Anestesiol 67 292–297
Mannning A (2002) Staph vaccine reduces infection risk from hospitals. USA TODAY Tuesday April 25
Geerts L, Jorens PG, Willems J, et al (2001) Natural inhibitors of neutrophil function in acute respiratory distress syndrome. Crit Care Med 29:1920–1924
Zeiher BG, Matsuoka S, Kawabata K, Repine JE (2002) Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit Care Med 30:S281-S286
Tanowitz HB, Weiss LM, Chan J (2002) Neutrophil migration and sepsis. Crit Care Med 30:1169–1170
Grafhorst JP van, Foudraine NA, Nooteboom F, et al (2002) Unexpected high risk of contamination with staphylococci species attributable to standard preparation of syringes for continuous intravenous dmg administration in a simulation model in intensive care units. Crit Care Med 30:833–836
Koss WG, Khalili TM, Lemus JF (2002) Nosocomial pneumonia is not prevented by protective contact isolation in the surgical intensive care unit. J Am Coll Surg 297:1140–1148
Wang P, Zheng FB, Zhou M, et al (1993) Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. Surgery 114:352–359
Bacher A, Mayer N, Klimscha W, et al (1997) Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 25:795–800
Fourrier F, Chopin C, Huart JJ, et al (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882–888
Inthom D, Hoffmann JN, Hartl WH, et al (1997) Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 8:328–334
Bryg DJ, Beale RJ (1998) Clinical effects of enteral immunonutrition on intensive care patients: a meta-analysis. Crit Care Med 26:A91
Durham RM, Neunaber K, Mazuski JE, et al (1996) The use of oxygen consumption and delivery as endpoints for resuscitation in criticaUy ill patients. J Trauma 41:32–40
Avontour JA, Tutein Nolthenius RP, Bodegom JW van, Bmining HA (1998) Prolonged inhibition of nitric oxide synthesis in severe septic shock. Crit Care Med 26:660–667
Ishikawa K, Tanaka H, Nakamori Y, et al (2000) Difference in the responses followmg granulocyte colony-stimulating factor (G-CSF) administration to septic patients with relative neutropenia. J Trauma Injury Infect Crit Care 48:814–825
Philhps JO, Metzler MH, Palmieri MTL, et al (1996) A prospective smdy of simphfied omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 24:1793–1800
O’Keefe GE, Gentilello LM, Maier RV (1998) Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg 227:120–125
Sun X, Wagner DP, Knaus WA (1996) Does selective decontamination of the digestive tract reduce mortahty for severely ill patients? Crit Care Med 24:753–755
Luiten EJ, Hop WCJ, Lange JF, Bruining HA (1995) Controlled clmical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 222:57–65
Dellinger RP, Zinmierman JL, Taylor RW, et al (1998) Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 26:15–23
Zapol WM (1998) Nitric oxide inhalation in acute respiratory distress syndrome: it works, but can we prove it? Crit Care Med 26:2–3
Mathisen DJ, Kuo EY, Hahn C, et al (1998) Inhaled nitric oxide for adult respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 65:1894–1902
Shoemaker WC, Appel PL, Kram HB, et al (1988) Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94:1176–1188
Thangathurai D, Charbonnet C, Wo CCJ, et al (1996) Intraoperative maintenance of tissue perfusion prevents ARDS. New Horiz 4:466–474
Kingsnorth AN, Galloway SW, Formela LJ (1995) Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor receptor antagonist in human acute pancreatitis. Br J Surg 82:1414–1420
Hirasawa H, Sugai T, Oda S, et al (1998) Continuous hemodiafiltration (Chdf) removes cytokine and improves respiratory index (Ri) and oxygen metabohsm in patients with acute respiratory distress syndrome (Ards). Crit Care Med 26:A120
Honore PM, James J, Wauthier M, et al (1998) Reversal of intractable circulatory failure complicating septic shock with short time high volume haemofiltration (ST-HV-CWH) after failure of conventional therapy: a prospective evaluation. Crit Care Med 2:62
Kolla S, Awad SS, Rich PB, et al (1997) Extracorporeal life support for 100 aduh patients with severe respiratory failure. Ann Surg 226:544–566
Gentielello LM, Jurkovich GJ, Stark MS, et al (1997) Is hypothermia in the victim of major trauma protective or harmful? Ann Surg 226:439–449
Meijer C, Wiezer MJ, Hack CE, et al (2001) Coagulopathy following major liver resection: the effect of rBPI21 and the role of decreased synthesis of regulating proteins by the liver. Shock 15:261–271
Wall P, Foley M, Raymond F, et al Enalaprilat during resuscitation increases temperamre and improves survival. Shock [Suppl 11] 99:A77
Forceville X, Vitoux D, Gauzit R, et al (1998) Selenium systemic immune response syndrome, sepsis and outcome in cktically ill patients. Crit Care Med 26:1536–1544
Vincent JL, Brasse R, Santman F, et al (2001) A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 27:1578–1583
Fronhoffs S, Luyken J, Steuer K, et al (2000) The effect of CI-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Intensive Care Med 26:1566–1570
Staudinger T, Kofler J, Mullner M, et al (2001) Comparison of prone positioning and continuous rotation of patients with adult respiratory distress syndrome: results of a pilot study. Crit Care Med; 29:51–56
Lynch RE (2002) Lisofylhne: anti-acute respiratory distress syndrome or just anti-inflammatory? Crit Care Med 30:246–247
Moore EE (1991) Hypertonie sahne dextran for post-injury resuscitation: experimental background and clinical experience. Aust N Z J Surg 61:732–736
Shackford SR, Bourguignon PR, Wald SL, et al (1998) Hypertonic sahne resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 44:50–58
Levine EA, Rosen AL, Sehgal LR, et al (1989) Treatment of acute postoperative anemia with recombinant human erythropoietin. J Trauma 29:1134–1138
Schinkel C, Licht K, Zedier S, et al (2001) Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind chnical trial. Shock 16:329–333
Nathens AB, Neff M, Jurkovich GH, et al (2001) Antioxidant supplementation in the critically ill surgical patients. Program of SIS 34:A12
Ferrando AA, Sheffield-Moore M, Wolf SE, et al (2001) Testosterone administration in severe bums ameliorates muscle catabolism. Crit Care Med 29:1936–1942
Napohtano LM (2001) Testosterone administration in male bum patients: the good, the bad, and the ugly. Crit Care Med 29:2032–2033
Choudray-Lucas C, LeBever H, Cynobar L, et al (2000) Omithine a-ketoglutarate improves wound healing in severe bum patients: a prospective randomized double-blind trial versus isonitrogenous controls. Crit Care Med 28:1772–1776
Kirov MY, Evgenov OV, Evgenov NV, et al (2001) Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 29:1860–1867
Kotani N, Hashimoto H, Kushikata T, et al (2001) Intraoperative prostaglandin El improves antimicrobial and inflammatory responses in alveolar immune cells. Crit Care Med 29:1943–1949
Byme TA, Persinger RI, Young LS, et al (1999) A new treatment for patients with short bowel syndrome syndrome: growth hormone, glutamine and a modified diet. Ann Surg 222:243–255
Takala J, Ruokonen E, Webster NR, et al (1999) Increased mortahty associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785–792
LuiGen W, Wim LT, Lange JF, Bmining HA (1995) Controlled clinical trial of selective decontamination for the treatment of severe active pancreatitis. Ann Surg 222:57–65
Lingnau W, Berger J, Javorsky F, Benzer HY (1997) Selective gut decontamination in multiple trauma patients. A prospective randomized trial. J Trauma 42:687–694
Suter PM, Domenighetti G, Schaller M-D, et al (1994) iV-Acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest 105:190–194
Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30:S325-S330
Ledere JR (2002) Platelet glycoprotein Ilb/IIIa antagonists: lessons leamed from clinical trials and future directions. Crit Care Med 30:S332-S340
Douzinas EE, Pitaridis MT, Louris G, et al (2000) Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 28:8–15
Kress HG, Scheideweig C, Schmidt H, Silber R (1999) Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A-and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med 27:1281–1287
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Italia
About this paper
Cite this paper
Baue, A.E. (2003). Step (or leap) into the future. What is new in 2000 and beyond? An emphasis on endocrine failure. In: Gullo, A. (eds) Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.. Springer, Milano. https://doi.org/10.1007/978-88-470-2215-7_44
Download citation
DOI: https://doi.org/10.1007/978-88-470-2215-7_44
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0194-7
Online ISBN: 978-88-470-2215-7
eBook Packages: Springer Book Archive